• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of the mechanisms of pulmonary regenerative disorder for the development of therapies for chronic respiratory dysfunction caused by the SARS-CoV-2

Research Project

Project/Area Number 21K20767
Research Category

Grant-in-Aid for Research Activity Start-up

Allocation TypeMulti-year Fund
Review Section 0803:Pathology, infection/immunology, and related fields
Research InstitutionNational Institute of Infectious Diseases

Principal Investigator

Shiwa-Sudo Nozomi  国立感染症研究所, 感染病理部, 研究員 (40902416)

Project Period (FY) 2021-08-30 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
KeywordsSARS-CoV-2 / 動物モデル / 後遺症(Long COVID) / 新型コロナウイルス感染症 / ウイルス感染症
Outline of Research at the Start

現在、新型コロナウイルス感染症(COVID-19)の後遺症(Long COVID)が問題視されている。Long COVIDの症状には呼吸機能障害などが含まれるが、この呼吸機能障害がなぜ起こるか、またなぜ完全に回復に至らないのか、その原因は明らかとなっていない。
本研究は、新型コロナウイルス(SARS-CoV-2)感染初期から後期に至るまでの肺におけるウイルス感染細胞と組織幹細胞の発現動態に着目し、SARS-CoV-2感染による組織幹細胞応答の変化が肺の再生に与える影響を明らかにし、肺の再生障害機序の解明を目指す。

Outline of Final Research Achievements

Chronic respiratory dysfunction has been reported as one of the symptoms of the aftereffects of the SARS-CoV-2 infection (Long COVID), but the pathogenesis is unclear. In this study, we used our previously established small animal models of SARS-CoV-2 infection to investigate the expression and distribution of viral proteins, lung tissue, and tissue stem cell markers in the early stage of infection in the lungs. Histopathological examination revealed that club cells in bronchioles were the main initial site of infection and replication in the lungs of SARS-CoV-2-infected animals. It was suggested that since club cells were tissue stem cells that differentiated into alveolar epithelial cells after alveolar injury, SARS-CoV-2 infection of club cells may affect the regeneration of lung function. These findings provide insights into the pathogenesis of SARS-CoV-2 and the development of treatment for Long COVID.

Academic Significance and Societal Importance of the Research Achievements

SARS-CoV-2感染が全世界で拡大を続ける今日、約3割の患者に感染後1ヶ月経過しても様々なLong COVIDの症状が報告されている。幅広い年齢層で慢性的な呼吸機能障害の症状を訴える患者が報告されているにも関わらず、その病態は未だ解明されていないため患者の治療は対症療法に頼らざるをえない。また、研究報告数もワクチンや治療薬開発と比較して少ないのが現状である。動物種を超えてSARS-CoV-2の感染および複製部位を明らかにし、組織幹細胞の発現動態にも着目した本研究は、SARS-CoV-2の感染動態を理解する上で有用であり、Long COVIDの治療法開発における基盤的研究と位置づけられる。

Report

(3 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • Research Products

    (15 results)

All 2023 2022 2021

All Journal Article (10 results) (of which Peer Reviewed: 10 results,  Open Access: 7 results) Presentation (5 results)

  • [Journal Article] Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults2023

    • Author(s)
      Sonoyama Takuhiro、Iwata Satoshi、Shinkai Masaharu、Iwata-Yoshikawa Naoko、Shiwa-Sudo Nozomi、Hemmi Takuya、Ainai Akira、Nagata Noriyo、Matsunaga Nobuaki、Tada Yukio、Homma Tomoyuki、Omoto Shinya、Yokokawa Shibata Risa、Igarashi Kenji、Suzuki Tadaki、Hasegawa Hideki、Ariyasu Mari
    • Journal Title

      Vaccine

      Volume: 41 Issue: 11 Pages: 1834-1847

    • DOI

      10.1016/j.vaccine.2022.12.025

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters2023

    • Author(s)
      Shiwa-Sudo Nozomi、Sakai Yusuke、Iwata-Yoshikawa Naoko、Watanabe Shinji、Yamada Souichi、Kuroda Yudai、Yamamoto Tsukasa、Shirakura Masayuki、Fujisaki Seiichiro、Miyazaki Kaya、Miura Hideka、Nagata Shiho、Fukushi Shuetsu、Maeda Ken、Hasegawa Hideki、Suzuki Tadaki、Nagata Noriyo
    • Journal Title

      Journal of Virology

      Volume: 97 Issue: 1 Pages: 1-21

    • DOI

      10.1128/jvi.01366-22

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys2022

    • Author(s)
      Hashimoto Masayuki、Nagata Noriyo、Iwata-Yoshikawa Naoko、Shiwa-Sudo Nozomi、Sakai Yusuke、Shirakura Masayuki、Kishida Noriko、Arita Tomoko、Suzuki Yasushi、Watanabe Shinji、Asanuma Hideki、Sonoyama Takuhiro、Suzuki Tadaki、Omoto Shinya、Hasegawa Hideki
    • Journal Title

      Vaccine

      Volume: 40 Issue: 31 Pages: 4231-4241

    • DOI

      10.1016/j.vaccine.2022.05.081

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology2022

    • Author(s)
      Hemmi Takuya、Ainai Akira、Hashiguchi Takao、Tobiume Minoru、Kanno Takayuki、Iwata-Yoshikawa Naoko、Iida Shun、Sato Yuko、Miyamoto Sho、Ueno Akira、Sano Kaori、Saito Shinji、Shiwa-Sudo Nozomi、Nagata Noriyo、Tamura Koji、Suzuki Ryosuke、Hasegawa Hideki、Suzuki Tadaki
    • Journal Title

      Vaccine

      Volume: 40 Issue: 41 Pages: 5892-5903

    • DOI

      10.1016/j.vaccine.2022.08.049

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways2022

    • Author(s)
      Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M.
    • Journal Title

      Nat Commun . 2

      Volume: 13 Issue: 1 Pages: 6100-6100

    • DOI

      10.1038/s41467-022-33911-8

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice2022

    • Author(s)
      Homma Tomoyuki、Nagata Noriyo、Iwata-Yoshikawa Naoko、Shiwa-Sudo Nozomi
    • Journal Title

      Scientific Reports

      Volume: 12 Issue: 1 Pages: 20861-20861

    • DOI

      10.1038/s41598-022-25418-5

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection2022

    • Author(s)
      Iwata-Yoshikawa Naoko、Shiwa Nozomi、Sekizuka Tsuyoshi、Sano Kaori、Ainai Akira、Hemmi Takuya、Kataoka Michiyo、Kuroda Makoto、Hasegawa Hideki、Suzuki Tadaki、Nagata Noriyo
    • Journal Title

      Science Advances

      Volume: 8 Issue: 1 Pages: 1-17

    • DOI

      10.1126/sciadv.abh3827

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T?cell responses2022

    • Author(s)
      Ishii H, Nomura T, Yamamoto H, Nishizawa M, Thu Hau TT, Harada S, Seki S, Nakamura-Hoshi M, Okazaki M, Daigen S, Kawana-Tachikawa A, Nagata N, Iwata-Yoshikawa N, Shiwa N, Suzuki T, Park ES, Ken M, Onodera T, Takahashi Y, Kusano K, Shimazaki R, Suzaki Y, Ami Y, Matano T
    • Journal Title

      Cell Reports Medicine

      Volume: 3 Issue: 2 Pages: 100520-100520

    • DOI

      10.1016/j.xcrm.2022.100520

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants2022

    • Author(s)
      Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Fukushi S, Takahashi Y, Suzuki T et al.
    • Journal Title

      Med

      Volume: 3 Issue: 4 Pages: 249-261

    • DOI

      10.1016/j.medj.2022.02.006

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants2022

    • Author(s)
      Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y
    • Journal Title

      Antiviral Research

      Volume: 201 Pages: 105297-105297

    • DOI

      10.1016/j.antiviral.2022.105297

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] 新型コロナウイルス既感染ハムスターにおけるオミクロン株再感染の可能性2022

    • Author(s)
      志和(須藤)希、渡邉真治、岩田(吉河)奈織子、坂井祐介、長谷川秀樹、鈴木忠樹、永田典代
    • Organizer
      第69回日本ウイルス学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] マウスモデルを用いたSARS-CoV-2感染におけるTMPRSS2の役割についての解析2022

    • Author(s)
      岩田 (吉河) 奈織子、柿崎政敏、志和希、大倉喬、田原舞乃、福士秀悦、前田健、川瀬みゆき、冨田有里子、高山郁代、松山州徳、白戸憲也、鈴木忠樹、竹田誠、永田典代
    • Organizer
      第69回日本ウイルス学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] ODN2006をアジュバントとする経鼻COVID-19ワクチンは広域中和能を有するIgA抗体を誘導し、ワクチン関連呼吸器疾患増強のリスクを軽減できる2022

    • Author(s)
      逸見拓矢、相内章、橋口隆生、飛梅実、菅野隆行、岩田(吉河)奈織子、飯田俊、佐藤由子、宮本翔、上野朗、佐野芳、齋藤慎二、志和(須藤)希、永田典代、田村浩二、鈴木亮介、長谷川秀樹、鈴木忠樹
    • Organizer
      第69回日本ウイルス学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] SARS-CoV-2における懸念される変異株(VOCs)の性質解析2022

    • Author(s)
      柿崎正敏、岩田 (吉河) 奈織子、 志和希、大倉喬、田原舞乃、福士秀悦、前田健、川瀬みゆき、冨田有里子、高山郁代、松山州徳、白戸憲也、鈴木忠樹、永田典代、竹田誠
    • Organizer
      第69回日本ウイルス学会学術集会
    • Related Report
      2022 Annual Research Report
  • [Presentation] 動物モデルを用いたSARS-CoV-2の感染および複製部位に関する病理学的研究2021

    • Author(s)
      志和希、岩田(吉河)奈織子、片岡紀代、長谷川秀樹、鈴木忠樹、永田典代
    • Organizer
      第68回日本ウイルス学会学術集会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-10-22   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi